Market Overview - A-shares market showed a slight decline on the morning of September 3, with major indices experiencing minor adjustments, while the ChiNext index briefly strengthened [1][2][5] - The Shanghai Composite Index opened high but fell, with a drop exceeding 40 points at one point, while the Shenzhen Component Index performed relatively well [5] Individual Stock Performance - Despite the overall market adjustment, individual stocks remained active, with several stocks hitting the daily limit up [2][9] - EVE Energy saw a significant increase, with an intraday rise exceeding 14%, and its market capitalization fluctuated around 130 billion yuan [5] - Another leading stock in the ChiNext, Sungrow Power Supply, also surged, with an intraday increase of over 10%, bringing its latest market capitalization to over 220 billion yuan [5] Sector Performance - In terms of industry sectors, internet, comprehensive, electrical equipment, and semiconductor sectors led the gains, while multi-financial and transportation equipment sectors lagged [6] - Concept sectors such as lithography machine and electronic paper saw strong performance, with lithium mining concepts also performing well, although their gains narrowed later [7] Stock Trading Alerts - DeXin Technology hit the daily limit up for the fourth consecutive trading day, issuing a risk alert due to significant price fluctuations [10] - Bojie Co. also reached the daily limit up for the third consecutive day, confirming no undisclosed matters affecting its stock price [11] - Baiyin Nonferrous Metals hit the daily limit up for the third consecutive day, with a significantly high static P/E ratio compared to its industry peers [12] Hong Kong Market Overview - The Hong Kong market opened high but turned lower, with the Hang Seng Index experiencing a decline [13][14] - Among the Hang Seng Index constituents, companies like Zhongsheng Holdings, CSPC Pharmaceutical Group, and Xinyi Solar saw notable gains [15] Company Earnings - NIO Inc. reported its Q2 2025 earnings, with total revenue of 19.0087 billion yuan (approximately 2.6535 billion USD), a 9.0% increase year-over-year and a 57.9% increase quarter-over-quarter [16] - The net loss for NIO in Q2 2025 was 4.9948 billion yuan (approximately 0.6972 billion USD), a decrease of 1.0% year-over-year and 26.0% quarter-over-quarter [16] - NIO's vehicle delivery volume reached 72,056 units in Q2 2025, marking a 25.6% increase year-over-year and a 71.2% increase quarter-over-quarter [16] Stock Performance in Hong Kong - Neway Group experienced a significant drop, with an intraday decline exceeding 16%, despite reporting strong financial performance for the year ending June 30, 2025 [17]

Group 1 - The latest shareholder equity disclosures for three companies: Vanguard Medical Biotechnology (00399), Huaxin Cement (06655), and CSPC Pharmaceutical Group (01093) were made on September 3, 2025 [1] Group 2 - Vanguard Medical Biotechnology: - Shareholder Mao Yumin reduced holdings from 1.55 billion shares to 1.50 billion shares, holding percentage decreased from 72.33% to 70.00% [2] - Huaxin Cement: - Shareholder Li Yeqing increased holdings from 454,000 shares to 508,600 shares, holding percentage increased from 0.03% to 0.04% [2] - CSPC Pharmaceutical Group: - Shareholder Cai Xin increased holdings from 50,000 shares to 100,000 shares, holding percentage remained at 0% [2]

智通财经APP讯，石药集团(01093)发布公告，于2025年9月2日根据股份计划发行50万股。 ...

石药集团(01093)发布公告，于2025年9月2日根据股份计划发行50万股。 ...

FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 石藥集團有限公司 呈交日期： 2025年9月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | ...

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 74.09%, Green Power Environmental (01330) at 70.24%, and China Shenhua (01088) at 67.86% [1] - Alibaba-W (09988), Meituan-W (03690), and Horizon Robotics-W (09660) saw the largest increases in holding amounts over the last five trading days, with increases of +4.318 billion, +2.228 billion, and +1.588 billion respectively [1] - The companies with the largest decreases in holding amounts over the last five trading days include Pop Mart (09992) at -1.380 billion, Sino Biopharmaceutical (01093) at -1.136 billion, and Xiaomi Group-W (01810) at -1.116 billion [3] Hong Kong Stock Connect Holding Ratios - China Telecom (00728): 10.284 billion shares, 74.09% holding ratio [1] - Green Power Environmental (01330): 0.284 billion shares, 70.24% holding ratio [1] - China Shenhua (01088): 2.292 billion shares, 67.86% holding ratio [1] - Other notable companies include Kaisa New Energy (01108) at 67.54% and Tianjin Chuangye Environmental Protection (01065) at 64.61% [1] Recent Increases in Holdings - Alibaba-W (09988): +4.318 billion, +31.4964 million shares [1] - Meituan-W (03690): +2.228 billion, +21.6345 million shares [1] - Horizon Robotics-W (09660): +1.588 billion, +168.2526 million shares [1] - Other companies with significant increases include Ping An Insurance (02318) and Kangfang Biologics (09926) [1] Recent Decreases in Holdings - Pop Mart (09992): -1.380 billion, -4.475 million shares [3] - Sino Biopharmaceutical (01093): -1.136 billion, -10.3326 million shares [3] - Xiaomi Group-W (01810): -1.116 billion, -2.0667 million shares [3] - Other companies with notable decreases include SMIC (00981) and Innovent Biologics (01801) [3]

Investment Rating - The report maintains an "OUTPERFORM" rating for CSPC Pharmaceutical Group [2]. Core Views - The company's performance in 1H25 showed a revenue of CNY 13.3 billion, a year-on-year decrease of 18.5%, with a focus on licensing deals to enhance profits [14][16]. - The report anticipates that the second quarter of 2025 marked the bottom of the company's performance, with expectations for improvement in the second half of the year [4][16]. Financial Performance Summary - **1H25 Results**: Revenue was CNY 13.3 billion (-18.5% y-o-y), with finished drug revenue at CNY 10.2 billion (-24% y-o-y) and API revenue at CNY 2.1 billion (+12% y-o-y). Gross profit margin (GPM) was 65.6% (-5.9 percentage points) [14][15]. - **2Q25 Results**: Revenue reached CNY 6.3 billion (-14% y-o-y), with finished drug revenue at CNY 4.7 billion (-21% y-o-y). GPM was 64.0% (-6.7 percentage points) [15][16]. - **Net Profit**: Net profit attributable to shareholders was CNY 2.5 billion (-24% y-o-y) in 1H25 and CNY 1.1 billion (-24% y-o-y) in 2Q25 [14][15]. Business Development and Licensing Opportunities - The company is expected to secure three major out-licensing deals totaling over USD 5 billion within the year, with SYS6010 (EGFR ADC) anticipated to be a significant transaction [17][21]. - The report highlights the potential for the oral GLP-1 drug to expand into global markets, tapping into obesity, diabetes, and metabolic dysfunction-associated steatohepatitis (MASH) markets [17][21]. Clinical Development Progress - SYS6010 is progressing well in both domestic and international clinical trials, with over 1,000 patients enrolled globally [18][19]. - The management is actively pursuing multiple indications for SYS6010, including breast cancer and gastrointestinal tumors, with clinical trial plans expected to commence soon [18][19]. Valuation and Forecast Adjustments - Revenue forecasts for FY25 and FY26 have been adjusted to CNY 29.4 billion and CNY 31.2 billion, respectively, reflecting the impact of volume-based procurement and negotiations [21]. - The target price is set at HKD 13.11, based on a 2026 P/E ratio of 29.1x and an EPS forecast of HKD 0.45 [21].

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 2.67% on September 1, with a trading volume of 1.985 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of August 29, 2024, the fund's latest share count was 6.686 billion, with a total size of 6.403 billion yuan, reflecting a year-to-date increase of 1591.03% in shares and 1594.74% in size compared to the end of 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 91.54% during the tenure [2] - The top holdings of the fund include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings in the portfolio [2] - The fund's liquidity is strong, with a cumulative trading amount of 34.181 billion yuan over the last 20 trading days, averaging 1.709 billion yuan per day [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 石藥集團有限公司 | | | 呈交日期: | 2025年9月1日 | | | I. 法定/註冊股本變動 | 不適用 | | FF301 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 (A). 股份期權（根據發行人的股份期權計劃） | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號(如上市) | 01093 | | 說明 | | | | | | | | | 股份期權計劃詳情 | 上月底結存的股份期權數 目 | | 本月內變動 | | 本月底結存的股份期權數 目 | | 本月內因此發行的新股數 目 (A1) | ...

Group 1 - The Hong Kong innovative drug sector continues to rise, with the Hang Seng Innovative Drug Index up by 3.0% as of 10:48, and notable gains in stocks such as Innovent Biologics up over 6%, CanSino Biologics and CSPC Pharmaceutical Group up over 5% [1] - The Hang Seng Innovative Drug ETF (159316) has seen a trading volume exceeding 400 million yuan, with net inflows for four consecutive trading days, bringing its latest scale to 1.8 billion yuan [1] - The National Healthcare Security Administration has officially announced the preliminary review list of drugs for the 2025 medical insurance and commercial insurance innovative drug directory, featuring new drugs including the "million-dollar cancer drug" CAR-T products and several "first and only in the world" products [1] Group 2 - CITIC Securities anticipates a significant increase in innovative drug catalyst events in September, and the recent technology switch has alleviated the short-term speculative money previously accumulated in the sector, suggesting that innovative drugs may continue to rise after this adjustment [1] - The Hang Seng Innovative Drug Index has officially adjusted to exclude contract research organizations (CROs), achieving a "100% purity" index that more accurately reflects the overall performance of China's innovative drug companies [1] - Backtesting indicates that since the index's launch on July 10, 2023, the annualized return and Sharpe ratio have improved after excluding CROs, making the Hang Seng Innovative Drug ETF (159316) the only product tracking this index, aiding investors in precisely positioning themselves for opportunities in the innovative drug industry [1]